Javascript must be enabled to continue!
Polypharmacy as a Chronic Condition: A Diagnostic Mindset for Safer and Smarter Care
View through CrossRef
Polypharmacy is typically seen as an unavoidable consequence of multimorbidity and aging, with clinicians addressing complex medication lists unsystematically. In this perspective, we argue that polypharmacy should be managed as a chronic condition. Like diabetes or hypertension, for example, the medication burden shows persistence, progression in its absence despite active management, predictable complications (such as falls, delirium, renal injury, functional decline), and a need for structured surveillance. We introduce a pragmatic diagnostic framework that moves beyond pill counts to modality-agnostic, regimen-level risk across prescribed and non-prescribed medicines. Diagnosis rests on prolonged exposure, composite burden indices (e.g., anticholinergic/sedative load), medication-related complications or prescribing cascades, and the need for a planned review. As biologics, gene therapies and long-acting formulations can lower tablet numbers while increasing monitoring, administration, and interaction complexity. We treat polypharmacy as cumulative pharmacodynamic and operational burden. We advocate stage matched care with unique, functional aims—decreasing the harmful burden instead of mass deprescribing—and position a structured medication review as the standard for polypharmacy with support from pharmacists, shared decision making, and safety netted taper plans. The framework fosters patient-centred care, embedding continuity and equity, and outlines a concise outcome set that integrates pharmacometric measures with patient-reported function and treatment burden. At the systems level, the framework enables registries, recall systems, decision support, and audit/feedback mechanisms to shift from sporadic medication list clean-up to a structured, measurable long-term program. Redefining polypharmacy in this way aligns clinical practice, education, and policy with real-world evidence, fostering a cohesive pathway to safer, streamlined, and more patient-centred care in community settings.
Title: Polypharmacy as a Chronic Condition: A Diagnostic Mindset for Safer and Smarter Care
Description:
Polypharmacy is typically seen as an unavoidable consequence of multimorbidity and aging, with clinicians addressing complex medication lists unsystematically.
In this perspective, we argue that polypharmacy should be managed as a chronic condition.
Like diabetes or hypertension, for example, the medication burden shows persistence, progression in its absence despite active management, predictable complications (such as falls, delirium, renal injury, functional decline), and a need for structured surveillance.
We introduce a pragmatic diagnostic framework that moves beyond pill counts to modality-agnostic, regimen-level risk across prescribed and non-prescribed medicines.
Diagnosis rests on prolonged exposure, composite burden indices (e.
g.
, anticholinergic/sedative load), medication-related complications or prescribing cascades, and the need for a planned review.
As biologics, gene therapies and long-acting formulations can lower tablet numbers while increasing monitoring, administration, and interaction complexity.
We treat polypharmacy as cumulative pharmacodynamic and operational burden.
We advocate stage matched care with unique, functional aims—decreasing the harmful burden instead of mass deprescribing—and position a structured medication review as the standard for polypharmacy with support from pharmacists, shared decision making, and safety netted taper plans.
The framework fosters patient-centred care, embedding continuity and equity, and outlines a concise outcome set that integrates pharmacometric measures with patient-reported function and treatment burden.
At the systems level, the framework enables registries, recall systems, decision support, and audit/feedback mechanisms to shift from sporadic medication list clean-up to a structured, measurable long-term program.
Redefining polypharmacy in this way aligns clinical practice, education, and policy with real-world evidence, fostering a cohesive pathway to safer, streamlined, and more patient-centred care in community settings.
Related Results
A Comprehensive Investigation Into The Effects of Mindset
A Comprehensive Investigation Into The Effects of Mindset
Why do some adolescents struggle more with academic setbacks and challenges than others? Professor Carol Dweck’s research highlights the importance of mindset—beliefs about one’s a...
1494. Impact of Polypharmacy on Gait Speed and Falls in Older People Living with HIV.
1494. Impact of Polypharmacy on Gait Speed and Falls in Older People Living with HIV.
Abstract
Background
Older people living with HIV (PWH) are uniquely prone to polypharmacy because of the increased medication bu...
Reframing Polypharmacy: Empowering Medical Students to Manage Medication Burden as a Chronic Condition
Reframing Polypharmacy: Empowering Medical Students to Manage Medication Burden as a Chronic Condition
Aims/Background: Polypharmacy, or the concurrent intake of five or more medications, is a significant issue in clinical practice, particularly in multimorbid elderly individuals. D...
Clinical factors associated with multimorbidity, polypharmacy and medication regimen complexity among adults with hypertension: a multicentre cross-sectional study
Clinical factors associated with multimorbidity, polypharmacy and medication regimen complexity among adults with hypertension: a multicentre cross-sectional study
Objectives
Factors associated with multimorbidity, polypharmacy and Medication Regimen Complexity Index (MRCI) may vary across countries. However, such data are l...
Suffering of Patients with Neurogenic Thoracic Outlet Syndrome (TOS); The First Qualitative study in TOS
Suffering of Patients with Neurogenic Thoracic Outlet Syndrome (TOS); The First Qualitative study in TOS
Abstract
Background
Diagnosis of neurogenic thoracic outlet syndrome (nTOS) is hindered by symptom overlap with cervical radiculopathy, carpal tunnel syndrome, or psychosomatic dis...
Antipsychotic Polypharmacy among Children and Young Adults in Office-Based or Hospital Outpatient Department Settings
Antipsychotic Polypharmacy among Children and Young Adults in Office-Based or Hospital Outpatient Department Settings
The purpose of the study was three-fold: (1) to estimate the national trends in antipsychotic (AP) polypharmacy among 6- to 24-year-old patients in the U.S.; (2) to identify freque...
The Burden of Potentially Inappropriate Medications in Chronic Polypharmacy
The Burden of Potentially Inappropriate Medications in Chronic Polypharmacy
We aimed to describe the burden represented by potentially inappropriate medications (PIMs) in chronic polypharmacy in France. We conducted a nationwide cross-sectional study using...
Polypharmacy and Psychological Distress May Be Associated in African American Adults
Polypharmacy and Psychological Distress May Be Associated in African American Adults
Background: Compared to Whites, African Americans are at a higher risk of multiple chronic conditions, which places them at a higher risk of polypharmacy. Few national studies, how...

